TheraRadar
Home/Indications/Clinically Isolated Syndrome

Clinically Isolated Syndrome

6 original drugs
6
Novel Drugs
5
Reformulations
0
Active Trials
10
Drug Targets

Clinically Isolated Syndrome has 6 FDA-approved novel treatments, led by Biogen across 10 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Clinically Isolated Syndrome Market Leaders

Companies with the most FDA-approved novel Clinically Isolated Syndrome drugs.

Clinically Isolated Syndrome Treatments by Mechanism

Top 2 mechanisms across 3 industry trials with a known mechanism of action.

See full pipeline →
CD20-directed Cytolytic Antibody
2 trials 1 sponsor
Interferon beta
1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinically Isolated Syndrome Clinical Pipeline by Phase

6 industry-sponsored trials across 4 sponsors

Reformulations (5 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

Clinically Isolated Syndrome Drug Targets

Molecular targets of approved and investigational Clinically Isolated Syndrome drugs — 10 targets tracked.

Biosimilars (1 BLA approved) Click to expand

Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.

Generic Drugs (4 ANDA approved) Click to expand

Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).

Drug Categories:

  • Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
  • Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
  • Biosimilars: BLA-approved biologics highly similar to reference products
  • Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology